» Articles » PMID: 36642171

Kupffer Cells Contested As Early Drivers in the Pathogenesis of Primary Sclerosing Cholangitis

Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic chronic immune-mediated cholestatic liver disease characterized by fibro-inflammatory bile duct strictures, progressive hepatobiliary fibrosis, and gut-liver axis disruption. The pathophysiology of PSC remains insufficiently characterized, which hampers the development of effective therapies. Hepatic macrophages (MFs) such as Kupffer cells (KCs) are implicated in PSC pathogenesis, but their exact role is unclear. Using the latest markers to discriminate resident KCs (ResKCs) from their monocyte-derived counterparts (MoKCs), and two models of intrahepatic and extrahepatic cholestasis, respectively, this study showed that CLEC4FTIM4 ResKCs were depleted after chronic cholestatic liver injury. The infiltrating CLEC4FTIM4 MoKCs were already enriched during the acute phase of PSC. Transcriptional profiling of hepatic MF subsets during early cholestatic injury indicated that ResKCs were indeed activated and that MoKCs expressed higher levels of pro-inflammatory and proliferative markers compared with those of ResKCs. As indicated in experiments with Clec4f transgenic mice, conditional depletion of KCs, before and during early cholestasis induction, had no effect on the composition of the hepatic myeloid cell pool following injury progression and did not affect disease outcomes. Taken together, these results provide new insights into the heterogeneity of the MF pool during experimental PSC and evidence that depletion of resident and activated KCs during sclerosing cholangitis does not affect disease outcome in mice.

Citing Articles

The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies.

Ma X, Qiu J, Zou S, Tan L, Miao T Front Immunol. 2024; 15:1494250.

PMID: 39635524 PMC: 11616179. DOI: 10.3389/fimmu.2024.1494250.


Central role for cholangiocyte pathobiology in cholestatic liver diseases.

Jalan-Sakrikar N, Guicciardi M, OHara S, Azad A, LaRusso N, Gores G Hepatology. 2024; .

PMID: 39250501 PMC: 11890218. DOI: 10.1097/HEP.0000000000001093.


Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.

Zhao J, Yue P, Mi N, Li M, Fu W, Zhang X Med Rev (2021). 2024; 4(4):326-365.

PMID: 39135601 PMC: 11317084. DOI: 10.1515/mr-2024-0029.


Limitations of PLX3397 as a microglial investigational tool: peripheral and off-target effects dictate the response to inflammation.

Claeys W, Verhaege D, Van Imschoot G, Van Wonterghem E, Van Acker L, Amelinck L Front Immunol. 2023; 14:1283711.

PMID: 38077359 PMC: 10703484. DOI: 10.3389/fimmu.2023.1283711.